Article
Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for
Rating:
0.0
Views:
140
Likes:
1
Library:
1
Editas Medicine has received the FDA's blessing to enter the clinic with its first ex vivo cell therapy — but it will do so without CSO Charles Albright, who is leaving his post for the same gig at an early-stage company. The FDA clearance was announced minutes after Editas shared
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value